-
-
-
-
-
-
-
Zymeworks outlines 2026 strategy with potential $440M milestones
-
-
-
-
-
-
-
Zymeworks (ZYME) Announces $60M Share Buyback
-
-
-
-
-
-
-
Zymeworks Appoints New Director
-
-
-
-
-
-
-
Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer
-
-
-
-
-
-
-
Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors
-
-
-
-
-
-
-
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
-
-
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

